About

Our mission is to prevent blindness

Alkeus Pharmaceuticals is a late-stage biopharmaceutical company developing therapies for serious and untreatable diseases of the eye.

Alkeus’ lead drug candidate, ALK-001, is an oral investigational drug being studied in a Phase 2 clinical trial for the treatment of Stargardt disease and in a Phase 3 clinical trial for the treatment of Geographic Atrophy secondary to dry age-related macular degeneration (AMD).

Stargardt Disease is the number one cause of genetic blindness in children and young adults. Dry age-related macular degeneration is the number one cause of unpreventable blindness in the United States.

ALK-001 has been granted Breakthrough Therapy Designation and Orphan Drug Designation by the United States FDA.

Learn More About Our Pipeline »